Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Guanylin
Overview
Guanylin is a 15-amino acid endogenous peptide hormone that activates guanylate cyclase-C (GC-C) receptors on intestinal epithelial cells. Upon binding, it stimulates intracellular cyclic GMP production, which regulates chloride and bicarbonate secretion into the intestinal lumen and promotes fluid secretion.
Mechanism of Action
This mechanism enhances intestinal motility and fluid balance. Guanylin functions as a paracrine regulator of intestinal homeostasis and salt-water equilibrium.
Research Summary & Key Findings
Guanylin itself has been characterized primarily in preclinical studies elucidating its role in intestinal fluid regulation and epithelial cell function. Synthetic analogs of guanylin, such as linaclotide and plecanatide, have been developed and approved for clinical use in chronic constipation and irritable bowel syndrome with constipation. Native guanylin remains a research tool rather than a therapeutic agent.
Clinical Status
Guanylin is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "Guanylin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Guanylin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Guanylin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Gastrointestinal
Octreotide (Sandostatin)
FDA ApprovedA synthetic octapeptide analog of somatostatin with a substantially longer half-life (90 minutes IV, 6 hours subcutaneou...
View detailsLanreotide (Somatuline Depot)
FDA ApprovedA synthetic octapeptide analog of somatostatin with high affinity for SSTR2 and moderate affinity for SSTR5 receptors. L...
View detailsPasireotide (Signifor)
FDA ApprovedA multireceptor-targeted somatostatin analog with high binding affinity for SSTR1, SSTR2, SSTR3, and SSTR5, particularly...
View detailsPlecanatide (Trulance)
FDA ApprovedA synthetic 16-amino acid peptide structurally related to uroguanylin, an endogenous intestinal peptide that regulates f...
View detailsNo lawful pathway today
Guanylin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.